Sensei Biotherapeutics Inc
$ 9.00
-2.81%
26 Dec - close price
- Market Cap 11,351,600 USD
- Current Price $ 9.00
- High / Low $ 9.27 / 9.00
- Stock P/E N/A
- Book Value 18.24
- EPS -19.14
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.37 %
- ROE -0.70 %
- 52 Week High 18.35
- 52 Week Low 5.00
About
Sensei Biotherapeutics, Inc. is a clinical-stage immunotherapy company based in Rockville, Maryland, specializing in pioneering cancer therapies that harness the body's immune system. The company's robust pipeline features innovative treatments designed to effectively stimulate immune responses to target and eliminate tumors. With a strategic commitment to advancing biotechnology and improving patient outcomes, Sensei is well-equipped to play a significant role in the evolving oncology landscape, addressing the growing need for efficacious and targeted cancer treatments.
Analyst Target Price
$32.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-14 | 2025-08-05 | 2025-05-07 | 2025-02-26 | 2024-11-05 | 2024-08-06 | 2024-05-09 | 2024-02-28 | 2023-11-07 | 2023-08-03 | 2023-05-09 | 2023-03-28 |
| Reported EPS | -3.62 | -3.91 | -0.2725 | -0.2728 | -0.29 | -0.28 | -0.32 | -0.3 | -0.28 | -0.31 | -0.33 | -0.4 |
| Estimated EPS | -0.23 | -0.24 | -0.26 | -0.29 | -0.31 | -0.29 | -0.28 | -0.31 | -0.34 | -0.33 | -0.36 | -0.4 |
| Surprise | -3.39 | -3.67 | -0.0125 | 0.0172 | 0.02 | 0.01 | -0.04 | 0.01 | 0.06 | 0.02 | 0.03 | 0 |
| Surprise Percentage | -1473.913% | -1529.1667% | -4.8077% | 5.931% | 6.4516% | 3.4483% | -14.2857% | 3.2258% | 17.6471% | 6.0606% | 8.3333% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SNSE
2025-12-11 19:09:50
Sensei Biotherapeutics Inc. (NASDAQ: SNSE) experienced a significant after-hours jump of nearly 63% on Thursday, reaching $17.20. This surge occurred after Cambrian BioPharma Inc., a 10% shareholder, filed two Form 144s with the SEC, indicating an intent to sell 27,066 common shares valued at $235,744. The company's stock has shown positive performance year-to-date and over the last six months.
2025-11-17 05:02:53
Sensei Biotherapeutics has significantly reduced its workforce by 65% and is exploring strategic alternatives, including a sale or merger. This move follows the closure of its Rockville, Maryland research site, although the company maintains office and lab space in Boston's Seaport district. This marks a dramatic shift for the biotech, which went public with $133 million just a few years ago.
2025-11-17 05:02:53
Sensei Biotherapeutics significantly narrowed its third-quarter loss to $4.6 million by cutting operating costs and reducing its staff by 65%. The biotech firm is now exploring mergers or asset sales to determine its future direction, signaling a strategic shift for both the company and the broader biotech sector. Despite these drastic changes, analyst ratings remain positive, indicating continued investor optimism for the industry.
2025-11-17 03:13:00
Sensei Biotherapeutics Inc. is significantly reducing its workforce by 65% as it begins to explore options for a sale, merger, or other strategic deals. This move follows the closure of its Rockville, Maryland research site, leaving only about five employees remaining at the company. The biotech firm still maintains office and laboratory space in Boston's Seaport district.
2025-11-14 19:09:09
Sensei Biotherapeutics (SNSE) has decided to discontinue the development of its lead product candidate, Solnerstotug, and is reviewing strategic alternatives including a potential sale, merger, or asset licensing. The company plans to reduce its workforce to conserve cash and will not initiate a new clinical study for Solnerstotug due to funding needs and market conditions. Shares of SNSE rallied 5% following the announcement.
2025-11-14 10:33:00
Sensei Biotherapeutics has announced a 65% reduction in its workforce and the termination of three executive roles, including the CEO, CSO, and CBO. This follows previous layoffs and the discontinuation of its lead clinical-stage asset, solnerstotug, due to funding needs and market conditions. The company is now evaluating strategic alternatives, including asset sales or a complete wind-down.
